XRAY Investors Have Opportunity to Lead Dentsply Sirona Inc. Securities Fraud Lawsuit

04.12.24 22:27 Uhr

Werte in diesem Artikel

NEW YORK, Dec. 4, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Dentsply Sirona Inc. (NASDAQ: XRAY) between December 1, 2022 and November 6, 2024, both dates inclusive (the "Class Period"), of the important January 27, 2025 lead plaintiff deadline.

Rosen Law Firm, P.A. Logo

So what: If you purchased Dentsply common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Dentsply class action, go to https://rosenlegal.com/submit-form/?case_id=31762 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 13, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Dentsply targeted low-income people who did not have access to good oral hygiene education, a dentist, or dental insurance, which often meant patients signing up for Byte, a direct-to-consumer ("DTC") aligner solution, had underlying dental issues that would have made them ineligible for treatment; (2) the push for Byte growth and sales commissions caused sales employees to sell to contraindicated patients; (3) as a result of the above, the Byte patient onboarding workflow did not provide adequate assurance that contraindicated patients did not enter treatment; (4) before and during the Class Period, reports of Byte patient injuries were pouring in; (5) Dentsply knew that its Byte aligners were causing severe patient injuries for years but did little to investigate those injuries or notify the U.S. Food and Drug Administration ("FDA"); (6) Dentsply had no systems in place to notify the FDA of these injuries, which Dentsply is required to do within 30 days of learning of a problem; (7) the FDA had received a sharp uptick in reports of serious injuries from Byte patients; (8) as a result of the above, Dentsply materially overstated the goodwill value of Byte; and (9) as a result of the above, defendants' positive statements about Dentsply's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.  When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Dentsply class action, go to https://rosenlegal.com/submit-form/?case_id=31762 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      case@rosenlegal.com
      www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/xray-investors-have-opportunity-to-lead-dentsply-sirona-inc-securities-fraud-lawsuit-302322885.html

SOURCE THE ROSEN LAW FIRM, P. A.

Ausgewählte Hebelprodukte auf DENTSPLY SIRONA

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DENTSPLY SIRONA

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu DENTSPLY SIRONA Inc

Analysen zu DENTSPLY SIRONA Inc

DatumRatingAnalyst
09.07.2019DENTSPLY SIRONA NeutralH.C. Wainwright & Co.
30.05.2019DENTSPLY SIRONA Peer PerformWolfe Research
06.05.2019DENTSPLY SIRONA OutperformBarrington Research
06.05.2019DENTSPLY SIRONA NeutralH.C. Wainwright & Co.
04.03.2019DENTSPLY SIRONA NeutralH.C. Wainwright & Co.
DatumRatingAnalyst
06.05.2019DENTSPLY SIRONA OutperformBarrington Research
08.08.2018DENTSPLY SIRONA BuyStifel, Nicolaus & Co., Inc.
08.05.2018DENTSPLY SIRONA OutperformBarrington Research
05.03.2018DENTSPLY SIRONA OutperformBarrington Research
08.12.2017DENTSPLY SIRONA BuyDeutsche Bank AG
DatumRatingAnalyst
09.07.2019DENTSPLY SIRONA NeutralH.C. Wainwright & Co.
30.05.2019DENTSPLY SIRONA Peer PerformWolfe Research
06.05.2019DENTSPLY SIRONA NeutralH.C. Wainwright & Co.
04.03.2019DENTSPLY SIRONA NeutralH.C. Wainwright & Co.
09.08.2018DENTSPLY SIRONA Mkt PerformBarrington Research
DatumRatingAnalyst
22.10.2012DENTSPLY International sellUBS AG
14.09.2007Dentsply verkaufenGeldbrief

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DENTSPLY SIRONA Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"